Paradigm Biocapital Advisors LP Incyte Corp Transaction History

Paradigm Biocapital Advisors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $27.1 Million - $30.9 Million	-469,214 Reduced 33.96%	912,497 $52.7 Million
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $7.31 Million - $9.06 Million	120,000 Added 9.51%	1,381,711 $86 Million
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $28.7 Million - $35.2 Million	408,881 Added 47.94%	1,261,711 $91.2 Million
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $5.36 Million - $6.71 Million	79,748 Added 10.32%	852,830 $68.5 Million
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $14.4 Million - $18 Million	217,039 Added 39.03%	773,082 $51.5 Million
Q2 2022 Aug 15, 2022	BUY	$66.18 - $83.18 $21.3 Million - $26.8 Million	321,624 Added 137.2%	556,043 $42.2 Million
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $15.5 Million - $18.7 Million	234,419 New	234,419 $18.6 Million

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.